NZ717550B2 - Methods of treating or preventing cholesterol related disorders - Google Patents
Methods of treating or preventing cholesterol related disorders Download PDFInfo
- Publication number
- NZ717550B2 NZ717550B2 NZ717550A NZ71755012A NZ717550B2 NZ 717550 B2 NZ717550 B2 NZ 717550B2 NZ 717550 A NZ717550 A NZ 717550A NZ 71755012 A NZ71755012 A NZ 71755012A NZ 717550 B2 NZ717550 B2 NZ 717550B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- medicament
- use according
- patient
- monoclonal antibody
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 15
- 229940107161 Cholesterol Drugs 0.000 title claims description 7
- 235000012000 cholesterol Nutrition 0.000 title claims description 6
- 201000010099 disease Diseases 0.000 title claims description 6
- 239000003814 drug Substances 0.000 claims abstract description 30
- 102100005352 PCSK9 Human genes 0.000 claims abstract description 17
- 101700000651 PCSK9 Proteins 0.000 claims abstract description 17
- 238000008214 LDL Cholesterol Methods 0.000 claims abstract description 14
- 210000002966 Serum Anatomy 0.000 claims abstract description 14
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 23
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 208000004981 Coronary Disease Diseases 0.000 claims description 6
- 201000008739 coronary artery disease Diseases 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229940068977 Polysorbate 20 Drugs 0.000 claims description 2
- 229940068968 Polysorbate 80 Drugs 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 2
- 102100012475 LDLR Human genes 0.000 claims 2
- 108060004326 LDLR Proteins 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 229940030600 ANTIHYPERTENSIVES Drugs 0.000 claims 1
- 102000018616 Apolipoproteins B Human genes 0.000 claims 1
- 108010027006 Apolipoproteins B Proteins 0.000 claims 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 claims 1
- 229940096699 Bile acid sequestrants Drugs 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 206010062060 Hyperlipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- 229940030627 LIPID MODIFYING AGENTS Drugs 0.000 claims 1
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 1
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 Mevastatin Drugs 0.000 claims 1
- 102000004140 Oncostatin M Human genes 0.000 claims 1
- 108090000630 Oncostatin M Proteins 0.000 claims 1
- 102000024367 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 Pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N Pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 230000003276 anti-hypertensive Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- BRLDZKPJJNASGG-UHFFFAOYSA-N berbine Chemical compound C1=CC=C2CN3CCC4=CC=CC=C4C3CC2=C1 BRLDZKPJJNASGG-UHFFFAOYSA-N 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 239000000262 estrogen Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- -1 sulphonyl ureas Chemical compound 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 abstract description 17
- 108090001123 antibodies Proteins 0.000 abstract description 17
- 102000000853 LDL receptors Human genes 0.000 description 6
- 108010001831 LDL receptors Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000009576 Hypercholesterolemia Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008180 pharmaceutical surfactant Substances 0.000 description 3
- 210000003494 Hepatocytes Anatomy 0.000 description 2
- 102000025417 antigen binding proteins Human genes 0.000 description 2
- 108091000829 antigen binding proteins Proteins 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- CABVTRNMFUVUDM-MIGRVSMKSA-N 3-Hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-MIGRVSMKSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014486 Elevated triglyceride Diseases 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Disclosed and claimed is a method of lowering serum LDL cholesterol in a patient comprising administering at least one anti-PCSK9 antibody to the patient in need thereof at a dose of about 105-280mg wherein said dose is to be administered at a frequency of from once per week to once every four weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 15%. Wherein PCSK9 comprises the amino acids of SEQ ID NO 1 and the antibody is defined by 90% identity to SEQ Id NO: 23 and 49 or by the CDRs therein. , and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 15%. Wherein PCSK9 comprises the amino acids of SEQ ID NO 1 and the antibody is defined by 90% identity to SEQ Id NO: 23 and 49 or by the CDRs therein.
Description
(12) Granted patent specificaon (19) NZ (11) 717550 (13) B2
(47) Publicaon date: 2021.12.24
(54) METHODS OF TREATING OR PREVENTING CHOLESTEROL RELATED DISORDERS
(51) Internaonal Patent Classificaon(s):
A61K 39/395 C07K 16/40 A61P 3/06
(22) Filing date: (73) Owner(s):
2012.05.10 AMGEN INC.
(23) Complete specificaon filing date: (74) Contact:
2012.05.10 Spruson & Ferguson Pty Ltd
(62) Divided out of 618300 (72) Inventor(s):
CHAN, Joyce Chi Yee
(30) Internaonal Priority Data: GIBBS, John P.
US 61/484,610 2011.05.10 DIAS, Clapton S.
US 61/562,303 2011.11.21 WASSERMAN, Scott
US 61/595,526 2012.02.06
SCOTT, Robert Andrew Donald
US 61/614,417 2012.03.22 CLOGSTON, Christi L.
US 61/642,363 2012.05.03 OSSLUND, Timothy David
STEIN, Evan, A.
(57) Abstract:
Disclosed and claimed is a method of lowering serum LDL cholesterol in a paent comprising
administering at least one an-PCSK9 anbody to the paent in need thereof at a dose of about
105-280mg wherein said dose is to be administered at a frequency of from once per week to once
every four weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol
level by at least about 15%. Wherein PCSK9 comprises the amino acids of SEQ ID NO 1 and the
anbody is defined by 90% identy to SEQ Id NO: 23 and 49 or by the CDRs therein.
NZ 717550 B2
an elevated total serum cholesterol, elevated LDL, elevated triglycerides, elevated VLDL,
and/or low HDL. Hypercholesterolemia is, in fact, an established risk factor for coronary
heart disease (CHD) in humans. Lowering of low-density lipoprotein cholesterol (LDL-C)
results in a reduction of cardiovascular risk and is a primary goal in pharmacotherapy for
CHD. Statins (hydroxymethylglutaryl coenzyme A [HMG CoA] reductase inhibitors) are
currently the treatment of choice for hypercholesterolemia. However, emerging data indicate
that more aggressive treatment of hypercholesterolemia is associated with lower risk for CHD
events. In addition, a subset of patients are intolerant to, or do not respond adequately to,
statin therapy. Thus, novel therapies that can be used alone or in combination with existing
agents to more effectively reduce LDL-C may be useful.
It is well established that recycling of the hepatic cell surface low-density lipoprotein
receptor (LDLR) plays a critical role in the maintenance of cellular and whole body
cholesterol balance by regulating plasma LDL-C levels. More recently it has been shown
that proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the
recycling and regulation of LDLR. PCSK9 is a member of the subtilisin family of serine
proteases and is expressed predominantly in the liver. Following secretion, it causes post-
translational down regulation of hepatic cell surface LDLR by a mechanism that involves
direct binding to the LDLR. Down regulation of hepatic LDLR in turn leads to increased
levels of circulating LDL-C. Thus PCSK9 may represent a target for inhibition by novel
therapeutics in the setting of hypercholesterolemia. Strong rationale for such an approach is
available from studies in preclinical models and from findings that humans with PCSK9 loss-
of-function mutations have cholesterol levels lower than normal and reduced incidence of
CHD.
SUMMARY OF VARIOUS EMBODIMENTS
According to a first aspect, the present invention provides use of at least one
monoclonal antibody that specifically binds to PCSK9, or a fragment of said monoclonal
antibody that specifically binds to PCSK9, wherein PCSK9 comprises the amino acids of
SEQ ID NO 1, in the manufacture of a medicament for lowering serum LDL cholesterol level
in a patient in need thereof and/or treating or preventing a cholesterol related disorder in a
patient, wherein said medicament is to be administered to said patient at a dose of about 105
mg to about 280 mg of said monoclonal antibody or said fragment, wherein said dose is to be
administered at a frequency of from once per week to once every four weeks, and wherein
said medicament is capable of lowering said serum LDL cholesterol level by at least about
%, wherein said monoclonal antibody or said fragment comprises:
(a) a light chain variable region that comprises an amino acid sequence that is at least 90%
identical to that of SEQ ID NO:23 and a heavy chain variable region that comprises an
amino acid sequence that is at least 90% identical to that of SEQ ID NO:49; or
(b) a light chain complementarity determining region (CDR) of the CDRL1 sequence in
SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3
of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity
determining region (CDR) of the CDRH1 sequence in SEQ ID NO:49, a CDRH2 of
the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in
SEQ ID NO:49;
In some aspects of the invention a stable formulation comprising at least one
monoclonal antibody that specifically binds to PCSK9, wherein PCSK9 comprises the amino
acids of SEQ ID NO 1, the monoclonal antibody in an amount of about 40 mg/ml to about
300 mg/ml, and a pharmaceutically acceptable buffer in an amount of about .05 mM to about
40 mM, and a pharmaceutically acceptable surfactant in an amount that is about .01% w/v to
about 20% w/v, and at least one pharmaceutically acceptable stabilizer of about 0.5% w/v to
about 10% w/v, wherein the stable formulation has a pH of between about 4.0 to about 6.0 is
provided. In some embodiments the above stable formulation comprises a pharmaceutically
acceptable buffer chosen from thee group consisting of glutamate, phosphate, phosphate
buffered saline, sodium acetate, sodium citrate, and Tris buffer. In particular embodiments
the pharmaceutically acceptable buffer of the above stable formulation is present in an
amount of 10-20 mM. In a particular embodiment the pharmaceutically acceptable buffer is
sodium acetate in the amount of 10-20 mM. In some embodiments, the pharmaceutically
acceptable surfactant is present in an amount of about 0.004% w/v to about 0.01% w/v. In
particular embodiments the pharmaceutically acceptable surfactant of the above stable
formulation is polysorbate 80 or polysorbate 20. In further embodiments the
e.g.
e.g.
See, e.g., et al. Virology et al.
supra et al. Basic Methods in Molecular
Biology et al. Gene
e.g.
e.g.
i.e.
Computational Molecular Biology
et al.SIAM J. Applied Math.
et al. Nucl. Acid Res.
see et al.
Atlas of Protein Sequence and Structure
et al. Proc. Natl. Acad. Sci. U.S.A
et al. J. Mol. Biol.
et al.supra
e.g.
Immunology--A Synthesis
et al.
See, e.g.,
et al.
e.g.
e.g.
e.g.,
in vivo
see infra
See, e.g.,
Clin. Exp. Immunol. et al. J.
Immunol.
e.g.
i.e.
See, e.g., Fundamental Immunology
et al.
See, e.g.,
See, e.g., et
al. et al.
See, e.g., et al.
ab initio et al. Ab Initio
See, e.g., et al.,
See, e.g., et al.
et al.
e.g.
in vitro
e.g.
e.g.
e.g.
e.g. e.g.
see, e.g., et al. Methods in
Enzymology see, e.g., et al.
J. Immunol.
see, e.g., Antibodies, A Laboratory Manual
see, e.g., et al.
Molec. Immunol. see, e.g., et
al. Virology et al. Scand.
J. Immunol.
e.g.
e.g.
e.g.
See, e.g., et al. Molecular
Cloning: A Laboratory Manual
et al.
et al.
inter alia,
e.g.
e.g.
in vitro
1 nM, 1000pM to 500pM, 500 pM to 200 pM, less than 200 pM, 200 pM to 150 pM, 200 pM
to 100 pM, 100 pM to 10 pM, 10 pM to 1 pM.
One example of an IgG2 heavy chain constant domain of an anti-PCSK9 antibody of
the present invention has the amino acid sequence as shown in SEQ ID NO: 154, K.
One example of an IgG4 heavy chain constant domain of an anti-PCSK9 antibody of
the present invention has the amino acid sequence as shown in SEQ ID NO: 155, K.
One example of a kappa light chain constant domain of an anti-PCSK9 antibody has
the amino acid sequence as shown in SEQ ID NO: 157, K.
One example of a lambda light chain constant domain of an anti-PCSK9 antibody has
the amino acid sequence as shown in SEQ ID NO: 156, K.
Variable regions of immunoglobulin chains generally exhibit the same overall
structure, comprising relatively conserved framework regions (FR) joined by three
hypervariable regions, more often called “complementarity determining regions” or CDRs.
The CDRs from the two chains of each heavy chain/light chain pair mentioned above
typically are aligned by the framework regions to form a structure that binds specifically with
a specific epitope on the target protein (e.g., PCSK9). From N-terminal to C-terminal,
naturally-occurring light and heavy chain variable regions both typically conform with the
following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. A
numbering system has been devised for assigning numbers to amino acids that occupy
positions in each of these domains. This numbering system is defined in Kabat Sequences of
Proteins of Immunological Interest (1987 and 1991, NIH, Bethesda, MD), or Chothia &
Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883.
Various heavy chain and light chain variable regions are provided herein and are
depicted in FIGs. 2A-3JJ and 3LL-3BBB. In some embodiments, each of these variable
regions can be attached to the above heavy and light chain constant regions to form a
complete antibody heavy and light chain, respectively. Further, each of the so generated
heavy and light chain sequences can be combined to form a complete antibody structure.
Specific examples of some of the variable regions of the light and heavy chains of the
antibodies that are provided and their corresponding amino acid sequences are summarized in
TABLE 2.
TABLE 2: Exemplary Heavy and Light Chain Variable Regions
Antibody Light/Heavy
SEQ ID NO
30A4 5/74
3C4 7/85
23B5 9/71
25G4 10/72
31H4 12/67
27B2 13/87
25A7 15/58
27H5 16/52
26H5 17/51
31D1 18/53
20D10 19/48
27E7 20/54
30B9 21/55
19H9 22/56
26E10 23/49
21B12 23/49
17C2 24/57
23G1 26/50
13H1 28/91
9C9 30/64
9H6 31/62
31A4 32/89
1A12 33/65
16F12 35/79
22E2 36/80
27A6 37/76
28B12 38/77
28D6 39/78
31G11 40/83
13B5 42/69
31B12 44/81
3B6 46/60
5H5 421/419
24F7 425/423
22B11 429/427
30F1 433/431
24B9.1 437/435
24B9.2 441/439
20A5.1 445/443
20A5.2 449/447
20E5.1 453/451
20E5.2 457/455
8A3 461/459
11F1 465/463
12H11 469/467
11H4 473/471
11H8 477/475
11G1 481/479
8A1 485/483
Again, each of the exemplary variable heavy chains listed in Table 2 can be combined
with any of the exemplary variable light chains shown in Table 2 to form an antibody. Table
2 shows exemplary light and heavy chain pairings found in several of the antibodies disclosed
herein. In some instances, the antibodies include at least one variable heavy chain and one
variable light chain from those listed in Table 2. In other instances, the antibodies contain
two identical light chains and two identical heavy chains. As an example, an antibody or
antigen binding protein can include a heavy chain and a light chain, two heavy chains, or two
light chains. In some embodiments the antigen binding protein comprises (and/or consists) of
1, 2, and/or 3 heavy and/or light CDRs from at least one of the sequences listed in Table 2
(CDRs for the sequences are outlined in FIGs. 2A-3D, and other embodiments in FIGs.
3CCC-3JJJ and 15A-15D). In some embodiments, all 6 CDRs (CDR1-3 from the light
(CDRL1, CDRL2, CDRL3) and CDR1-3 from the heavy (CDRH1, CDRH2, and CDRH3))
are part of the ABP. In some embodiments, 1, 2, 3, 4, 5, or more CDRs are included in the
ABP. In some embodiments, one heavy and one light CDR from the CDRs in the sequences
in Table 2 is included in the ABP (CDRs for the sequences in table 2 are outlined in FIGs.
2A-3D). In some embodiments, additional sections (e.g., as depicted in -2D, 3A-3D,
and other
e.g.
e.g.,
e.g.
e.g.
e.g.
e.g.
See, e.g.,
See, e.g.,
See, e.g., et al.
See, e.g.,et al.
et al.
et al. .
See, e.g., et al. Mol Immunol
et al.
et al. et al.
e.g.
i.e.
e.g.
e.g.
see, e.g.,
Journal of Molecular Biology
see, e.g. Sequences of Proteins of Immunological
Interest
et al.,
et al.
et al. et al.
et al.
See et al.
et al.,
et al.
et al., et al.
et al.
supra , supra
Proteins, Structures and Molecular Principles
Introduction to Protein Structure
et al.
e.g.
e.g.
See, e.g.,
See, e.g.,
e.g.
See, e.g., et al.
et al. J Mol Biol
See, e.g., et al.,
et al.
e.g.
e.g.
in vitro
e.g. See, e.g., et al.,
et al.,
See, e.g., et al.,
et al.
See, e.g., et al.,
See, e.g.,
et al.
See, e.g., et al., et al.
See also et al.
e.g.
See also
et al.
et al.
See also
See further et al. et al.
et al. et al. et al. et al.
et al. et al.
et al
in vitro
e.g.
Pichia
Spodoptera
frugiperda
Autographa
californica
Spodoptera frugiperda Trichoplusia
S. frugiperda
Trichoplusia See, e.g., et al. et al.
See, e.g., et al. supra
See, e.g., et al.
e.g.
et al J. Biol. Chem
et al J. Biol. Chem.
e.g.
e.g.
e.g.
e.g.
e.g.
e.g.
Remington's Pharmaceutical
Sciences
Remington's Pharmaceutical Sciences
supra
in vivo in vivo
i.e.
Remington's Pharmaceutical Sciences supra
e.g.
et al.
et al.
al. supra
See, e.g., et al.
in vivo
e.g.
e.g.
Proinflammatory and Anti-Inflammatory Cytokines in
Rheumatoid Arthritis: A Primer for Clinicians
e.g.
See, e.g.
et al. J. Immunol.
e.g.
in vitro
e.g.
et al. Nucleic Acids Res.
see Molecular Biology and Evolution
Claims (23)
1. Use of at least one monoclonal antibody that specifically binds to PCSK9, or a fragment of said monoclonal antibody that specifically binds to PCSK9, wherein PCSK9 comprises the amino acids of SEQ ID NO 1, in the manufacture of a medicament for lowering serum LDL cholesterol level in a patient in need thereof and/or treating or preventing a cholesterol related disorder in a patient, wherein said medicament is to be administered to said patient at a dose of about 105 mg to about 280 mg of said monoclonal antibody or said fragment, wherein said dose is to be administered at a frequency of from once per week to once every four weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 15%, wherein said monoclonal antibody or said fragment comprises: (a) a light chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:23 and a heavy chain variable region that comprises an amino acid sequence that is at least 90% identical to that of SEQ ID NO:49; or (b) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO:49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49.
2. The use according to claim 1, wherein said medicament is capable of lowering said serum LDL cholesterol level by an amount selected from the group consisting of a) at least about 30%, b) at least about 40%, c) at least about 50%, and d) at least about 60%.
3. The use according to claim 1, wherein the cholesterol related disorder is selected from the group consisting of familial hypercholesterolemia including heterozygous familial hypercholesterolemia and homozygous familial hypercholesterolemia, non-familial hypercholesterolemia, elevated lipoprotein A, heart disease, metabolic syndrome, diabetes, coronary heart disease, stroke, cardiovascular disease, peripheral arterial disease, hyperlipidemia and dyslipidemia.
4. The use according to any one of claims 1 to 3, wherein said monoclonal antibody or said fragment comprises a light chain variable region that comprises the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:49.
5. The use according to any one of claims 1 to 4, wherein the said monoclonal antibody or said fragment comprises: (a) a light chain complementarity determining region (CDR) of the CDRL1 sequence in SEQ ID NO:23, a CDRL2 of the CDRL2 sequence in SEQ ID NO:23, and a CDRL3 of the CDRL3 sequence in SEQ ID NO:23, and a heavy chain complementarity determining region (CDR) of the CDRH1 sequence in SEQ ID NO:49, a CDRH2 of the CDRH2 sequence in SEQ ID NO:49, and a CDRH3 of the CDRH3 sequence in SEQ ID NO:49; or (b) a light chain complementarity determining region (CDR) CDRL1 comprising the amino acid sequence of SEQ ID NO: 158, a CDRL2 comprising the amino acid sequence of SEQ ID NO: 162, a CDRL3 comprising the amino acid sequence of SEQ ID NO: 395; a heavy chain complementarity determining region (CDR) CDRH1 comprising the amino acid sequence of SEQ ID NO: 368, a CDRH2 comprising the amino acid sequence of SEQ ID NO: 175, a CDRH3 comprising the amino acid sequence of SEQ ID NO: 180.
6. The use according to any one of claims 1 to 5, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment selected from the group consisting of: a) about 105 mg to about 140 mg, b) about 140 mg to about 280 mg, c) about 120 mg to about 200 mg, d) about 140 mg to about 200 mg, e) about 105 mg, f) about 120 mg, g) about 140 mg, h) about 210 mg, and i) about 280 mg.
7. The use according to any one of claims 1 to 6, wherein said medicament is to be administered to said patient on a schedule selected from the group consisting of: (1) once a week, (2) once every two weeks, and (3) once a month.
8. The use according to any one of claims 1 to 7 wherein said medicament is to be administered to said patient subcutaneously.
9. The use according to any one of claims 1 to 7, wherein said medicament is to be administered to said patient parenterally.
10. The use according to any one of claims 1 to 7, wherein said medicament is to be administered to said patient intravenously.
11. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient on a schedule selected from the group consisting of: (a) about 105 mg to about 280 mg once every 2 weeks (Q2W); (b) about 140 mg to about 280 mg once every two weeks (Q2W); and (c) at least about 140 mg once every two weeks (Q2W).
12. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 105 mg to about 280 mg once every two weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 30-50% for about 7-14 days.
13. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 120 mg.
14. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 140 mg.
15. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 160 mg.
16. The use according to any one of claims 1 to 10, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 140 mg once every two weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 30-50% for about 7-14 days.
17. The use according to any one of claims 1 to 8, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 140 mg subcutaneously once every two weeks, and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 30-50% for about 7-14 days.
18. The use according to any one of claims 1 to 17, wherein said medicament is to be administered to said patient before, after or with at least one other cholesterol-lowering agent.
19. The use according to claim 18, wherein the at least one other cholesterol lowering agent is selected from the group consisting of: statins, including, atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, Nicotinic acid, Fibric acid, Bile acid sequestrants, Cholesterol absorption inhibitor, lipid modifying agents, PPAR gamma agonists, PPAR alpha/gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents, including sulphonyl ureas, insulin, GLP-1 analogs, DDPIV inhibitors, ApoB modulators, MTP inhibitors and /or arteriosclerosis obliterans treatments, oncostatin M, estrogen, berbine and a therapeutic agent for an immune-related disorder.
20. The use according to claim 1, wherein said medicament is to be administered to said patient at a dose of said monoclonal antibody or said fragment of about 140 mg subcutaneously once every two weeks and wherein said medicament is capable of lowering said serum LDL cholesterol level by at least about 30%.
21. The use according to claim 20, wherein said monoclonal antibody comprises: a light chain variable region that comprises the amino acid sequence SEQ ID NO: 23 and a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO:49.
22. Use according to any one of claims 1 to 21, wherein the monoclonal antibody or said fragment is in a stable formulation, wherein the stable formulation comprises: (a) about 10 mM to about 20 mM sodium acetate; (b) about 2.0% to about 3.0% w/v proline; (c) about 0.01% w/v polysorbate 20 or polysorbate 80, and and wherein the pH of the formulation is about 5.0.
23. Use according to claim 22, wherein stable formulation comprises about 100mg/ml to about 200mg/ml of the monoclonal antibody or said fragment thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ734570A NZ734570B2 (en) | 2011-05-10 | 2012-05-10 | Methods of treating or preventing cholesterol related disorders |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161484610P | 2011-05-10 | 2011-05-10 | |
US61/484,610 | 2011-05-10 | ||
US201161562303P | 2011-11-21 | 2011-11-21 | |
US61/562,303 | 2011-11-21 | ||
US201261595526P | 2012-02-06 | 2012-02-06 | |
US61/595,526 | 2012-02-06 | ||
US201261614417P | 2012-03-22 | 2012-03-22 | |
US61/614,417 | 2012-03-22 | ||
US201261642363P | 2012-05-03 | 2012-05-03 | |
US61/642,363 | 2012-05-03 | ||
NZ618300A NZ618300B2 (en) | 2011-05-10 | 2012-05-10 | Methods of treating or preventing cholesterol related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ717550A NZ717550A (en) | 2021-08-27 |
NZ717550B2 true NZ717550B2 (en) | 2021-11-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220127348A1 (en) | Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor | |
JP6400768B2 (en) | Methods for treating or preventing cholesterol-related disorders | |
CN104619340A (en) | Stable formulations containing anti-pcsk9 antibodies | |
CA3021884A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
US20200199253A1 (en) | Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor | |
US20240197870A1 (en) | Methods for treating patients with refractory hypercholesterolemia | |
NZ717550B2 (en) | Methods of treating or preventing cholesterol related disorders | |
WO2021185344A1 (en) | Method for treating cholesterol-related diseases | |
EA040479B1 (en) | METHODS FOR TREATMENT OF HYPERLIPIDEMIA WITH ANGPTL8 INHIBITOR AND ANGPTL3 INHIBITOR | |
TW202417041A (en) | Uses of a monoclonal antibody that specifically binds to pcsk9 for treating or preventing cholesterol related disorders | |
NZ618300B2 (en) | Methods of treating or preventing cholesterol related disorders | |
NZ734570B2 (en) | Methods of treating or preventing cholesterol related disorders |